Oncolytics Biotech Inc
ONCY- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001129928
No open-market purchases or sales by Oncolytics Biotech Inc insiders were filed in the last 90 days; 76 institutions reported holding it in 13F filings for Q2 2026, worth $3.77M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +19 vs. previous quarter
- 76
- 13F valueReported value at the end of Q2 2026
- $3.77M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding ONCY, Q2 2026
No superinvestor reported holding ONCY at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Oncolytics Biotech Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 13, 2026 (view filing) | Mar 11 | 2 days | Parsons James T.Director | PPurchase | +10.0K | $1.03 | +$10.3K | +31.4%41.8K after | |
| Mar 13, 2026 (view filing) | Mar 12 | 1 day | Kelly JaredChief Executive Officer | PPurchase | +5.05K | $0.96 | +$4.85K | +4.6%114.0K after | |
| Feb 13, 2026 (view filing) | Feb 11-12 | 2 days | Seizinger Bernd R.Director | PPurchase | +100.0K | $0.838 | +$83.8K | +21.4%567.0K after | 2 lots |
| Feb 13, 2026 (view filing) | Feb 12 | 1 day | Pisano WayneDirector | PPurchase | +30.0K | $0.84 | +$25.2K | +6.5%492.4K after | |
| Feb 13, 2026 (view filing) | Feb 12 | 1 day | Look KirkChief Financial Officer | PPurchase | +12.0K | $0.84 | +$10.1K | +4.4%287.5K after | |
| Feb 13, 2026 (view filing) | Feb 11-12 | 2 days | Kelly JaredChief Executive Officer | PPurchase | +35.1K | $0.84 | +$29.5K | +47.5%109.0K after | 2 lots |
| Feb 13, 2026 (view filing) | Feb 12 | 1 day | Heineman Thomas CharlesChief Medical Officer | PPurchase | +12.1K | $0.83 | +$10.1K | +4.5%282.8K after | |
| Feb 13, 2026 (view filing) | Feb 12 | 1 day | Hagerman AllisonVP, Product Development | PPurchase | +10.0K | $0.83 | +$8.30K | +9.5%115.1K after | |
| Feb 13, 2026 (view filing) | Feb 12 | 1 day | Brown Deborah MargaretDirector | PPurchase | +25.0K | $0.85 | +$21.3K | +29.5%109.9K after | |
| Feb 13, 2026 (view filing) | Feb 11 | 2 days | Aromando AndrewChief Business Officer | PPurchase | +29.6K | $0.86 | +$25.5K | +116.1%55.1K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Oncolytics Biotech Inc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Marshall Wace, LLP | 745,350 | $708.1K | 0.00% | −114,481−13.3% | Reduced |
| XTX Topco Ltd | 260,903 | $247.8K | 0.00% | +151,145+137.7% | Added |
| Seeds Investor LLC | 258,306 | $245.4K | 0.03% | 00.0% | Unchanged |
| International Assets Investment Management, LLC | 201,260 | $181.3K | 0.01% | +201,260 | New |
| Connective Capital Management, LLC | 185,712 | $176.4K | 0.12% | +185,712 | New |
| Goldman Sachs Group Inc | 169,898 | $161.4K | 0.00% | +169,898 | New |
| Tocqueville Asset Management L.P. | 147,000 | $139.6K | 0.00% | −2,000−1.3% | Reduced |
| Everhart Financial Group, Inc. | 140,899 | $133.8K | 0.01% | +2,738+2.0% | Added |
| Susquehanna International Group, LLP | 134,129 | $127.4K | 0.00% | +92,806+224.6% | Added |
| PFG Investments, LLC | 128,300 | $121.9K | 0.00% | +75,400+142.5% | Added |